Severe aplastic anemia (sAA) is a bone marrow failure disorder which is mostly a consequence of immunologically mediated stem cell destruction. Allogeneic bone marrow transplantation (BMT) from a compatible donor provides long-term survival in 60 to 80% of sAA patients. However, graft rejection still remains a major problem, and a second allograft is an alternative for these patients. We retrospectively analyzed 34 patients who received a second BMT (BMT2), nine with primary graft failure (PGF) and 25 with transient engraftment (TE). The probability of survival at 13 years among PGF patients was 22% vs 60% for the TE group (P = 0.0068). Age (Ͻ17 vs Ͼ17 years), number of mononuclear cells (Ͻ3 vs Ͼ3 × 10 8 /kg) and year of transplant (1986-1991 vs 1992-1998) at BMT2 had no statistical influence on survival. A significant survival advantage was noted among TE patients (P = 0.0068), which was probably because of a longer intertransplant interval (Ͼ90 days). Furthermore, 90% of patients with positive blood cultures at BMT2 did not survive the procedure. We conclude that early detection of primary graft failure (PGF), followed by measures attempting to promote hematopoietic recovery (eg use of growth factors, further infusion of stem cells) may decrease mortality. Bone Marrow Transplantation (2001) 28, 941-944.
and 60 to 80% of patients are long-term survivors after the procedure. 2 However, graft rejection, despite a declining incidence in recent years, still remains a major problem in sAA patients after BMT. [3] [4] [5] A second allograft is an alternative for patients whose first transplant has failed. Recent results have shown improved survival after second transplants, 3 and longer intertransplant intervals have been an important factor contributing to this success. This study is a single institution, retrospective analysis on the outcome of 34 patients who received a second BMT (BMT2) for sAA.
Patients and methods
We performed allogeneic BMTs (BMT1) from an identical sibling donor with unmanipulated bone marrow in 245 sAA patients from November 1986 to December 1998. Because of graft failure (GF), 34 patients received a BMT2.
First transplant
The preparative regimen for 34 patients included cyclophosphamide (CY) alone (50 mg/kg intravenously for 4 consecutive days) for 27 patients, and CY (at 60 mg/kg intravenously for 2 consecutive days) plus busulfan (3 mg/kg orally for 4 consecutive days) for seven patients. Graft-versus-host disease (GVHD) prophylaxis was cyclosporin A (CsA) and methotrexate according to the Seattle protocol. 6 The median marrow cell dose infused was 3.43 × 10 8 kg (range 1.69 to 12.9 × 10 8 kg).
Second transplant
All patients received unmanipulated bone marrow as a stem cell source at BMT2, and GVHD prophylaxis was also CsA and methotrexate. 6 When ABO incompatibility was present, red blood cells were removed by starch sedimentation. Acyclovir prophylaxis for herpes virus infection and trimethropin-sulfametoxazole for Pneumocystis carinii infection were used in all patients. Details about patients are included (Table 1) .
Graft failure was classified as primary graft failure (PGF) when no hematological recovery in patients surviving Ͼ21 days post transplant occurred; and as transient engraftment (TE) when complete or partial recovery of hematopoiesis of donor origin was detected, followed by recurrent pancytopenia with markedly hypocellular marrow in the absence of graft-versus-host disease. 7 Immunosuppressive treatment with CsA and prednisone were given to TE patients before the BMT2, in an attempt to recover hematopoiesis. The Chi-square and Kaplan-Meier tests were used for statistical analysis.
Results
Thirty-four patients received BMT2; nine had PGF and 25 had TE ( Table 2 ). The overall survival of the entire group is 50% at approximately 13 years ( Figure 1 ).
PGF patients
Five of nine second transplants on patients with PGF were from the same donor, and four from another identical sibling. Three patients died shortly after BMT2 (days +8, +14 and +15). Three had no engraftment after BMT2, and died at days 40, 48 and 68. One patient, who did not engraft post-BMT1, had a partial recovery of granulopoiesis at day Table 2 Results of patients submitted to BMT2 
PGF TE

TE patients
Twenty-five patients with TE underwent BMT2. Twenty received the new graft from the same donor and five from a different identical sibling. Seventeen patients showed signs of complete engraftment. Two rejected the second graft at days +199 and +390. One died of acute congestive heart failure and bacterial infection, whereas the other is alive after receiving immunosuppressive therapy with recovery of his own hematopoiesis. One patient who had engrafted and who had bronchiolitis obliterans died secondary to pulmonary fungal infection (Candida pneumonitis) at day +476. Six patients with no engraftment and two with partial engraftment after BMT2 died between 12 and 64 days (median 17 days), six secondary to bacterial infection and two following massive pulmonary hemorrhage. Fifteen patients with TE are long-term survivors after BMT2. Twelve patients were considered infected at BMT2 (seven had positive bacterial blood cultures, of whom six died). Acute GVHD was diagnosed in two patients (one grade III and one grade II), and one evolved to limited chronic GVHD. Three patients had de novo limited chronic GVHD. The TE group probability of survival is 60% at approximately 13 years (Figure 2 ).
Statistics
Factors possibly influencing survival after BMT2, such as age, number of cells infused, period of transplant, intertransplant interval and category of GF were analyzed. Univariate analysis showed that a longer intertransplant interval and TE were associated with improved survival (Table 3 ). However, both factors are probably associated, because patients with longer intertransplant intervals were most likely to be TE patients. Among TE survivors and non-survivors, no significant differences were detected in number of mononuclear cells infused at BMT2, intertransplant interval, GF to BMT2 interval, or immune suppression before BMT2. However, younger patients had a significantly better survival rate. Median ages among survivors and non-survivors were 13 years and 22 years, respectively (P = 0.038). Patients with documented infection (positive blood cultures) at BMT2 had a dismal prognosis, and nine of 10 patients with a positive blood culture succumbed to infection.
Discussion
In most patients with sAA, several insults -drugs, viruses, pregnancy, graft-versus-host disease -activate the immune system, leading to immune attacks and consequent destruction of bone marrow stem cells. Stromal cell failure or growth factor deficiencies are possible mechanisms in a few cases of sAA. 8 Replacement of injured stem cells with histocompatible marrow may cure sAA. However, serious complications may follow this procedure. Graft rejection, that occurred in 35% to 70% of patients in the mid-1970s, 9 is still a feared complication, despite a decreasing incidence over time.
3 Table 3 Analysis of factors possibly influencing survival after BMT2 
Bone Marrow Transplantation
A second marrow transplant is the treatment of choice for patients with no engraftment or graft rejection unresponsive to immunosuppressive therapy after BMT1. In the early 1970s, the Seattle group reported only one long-term survivor out of 22 patients receiving BMT2. 3 The brief intertransplant interval was directly related to the procedure failure and patients were more likely to die from transplantrelated toxicities. Stucki et al 3 published the recent Seattle experience with BMT2, in which time to rejection of the first graft increased (from 28 days to 180 days), as did the intertransplant interval. Survival rates also increased from 5% to 83%, in direct relation to the intertransplant interval. Guardiola et al 10 also described an intertransplant interval 80 days as a predictor of better outcome, in accordance with McCann et al 2 who noted similar results when analyzing patients receiving BMT2 more than 60 days from BMT1. As expected, when we compared the survival of the TE patients with regard to intertransplant interval -Ͻ90 days vs Ͼ90 days -we observed a significant advantage in those transplanted Ͼ90 days from BMT1 (P Ͻ 0.0001). Among the TE patients, whose median interval from BMT1 to graft failure was 253 days, the actuarial survival is 60% at approximately 13 years.
Type of graft failure 2 (PGF vs TE) and age (Ͻ18 years) 3 have been implicated with better survival after BMT2. Covariate analysis among our patients showed that TE patients had a significantly better survival than did PGF patients. However, age (Ͻ17 vs Ͼ17 years), number of cells infused (Ͻ3 vs Ͼ3 × 10 8 /kg), and period of transplant (1986-1991 vs 1992-1998) did not influence survival after BMT2.
Patients with PGF are severely immunosuppressed, have a short intertransplant interval and often have a complicating active infectious process (approximately 50% of our PGF patients had a positive blood culture at the BMT2).
McCann et al
2 also reported the poor outcome of PGF patients (actuarial survival of 17%), where infection was an important contributory factor and the majority of deaths were related to second graft failure. More aggressive conditioning regimens prior to BMT2 -associations of CY + ATG/ALG, CY + TBI or Busulfan + CY -in an attempt to overcome minor antigen disparities, did not secure engraftment in all of our PGF and TE patients. In fact, the two PGF patients who engrafted received the less immunosuppressive regimens. Intensification of conditioning regimens has not always been associated with improved survival and a reduction in graft failure may be offset by an increase in mortality. 4 Several factors are related to graft failure, such as intensity of conditioning regimen, number of stem cells infused, number of infused T cells, type of post-BMT immunosuppression, donor/recipient HLA-matching 11 and transfusions prior to BMT. 7 Graft rejection might even be intrinsic to the pathophysiology of sAA. 12 Despite a survival improvement among TE patients after BMT2, 2,3 benefit could not be demonstrated to PGF patients. Risk factors predicting PGF have not yet been described. However, 'resistance' to BMT2, 2 stromal cell abnormalities, 13 growth factor deficiencies, 7 in addition to the autoimmune process, are probable contributory factors. In spite of our small number of patients, univariate analysis of age, sex, number of mononuclear cells infused, number of transfusions, severity of sAA and presence of infection at BMT1 had no significant influence on the development of GF.
As identification of risk factors for PGF is not available, detection of graft failure before the occurrence of infection or hemorrhage should improve survival in these patients. Early treatment with growth factors (G-CSF or GM-CSF) between days 14 and 16 post BMT, when absolute neutrophil counts are Ͻ0.2 × 10 9 /l, must be considered.
14 If no response is observed after 5 to 7 days, a further infusion of G-CSF mobilized peripheral blood stem cells, with or without a new conditioning regimen, should be undertaken. 15, 16 
